Cited 628 times in
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2014-12-18T09:54:15Z | - |
dc.date.available | 2014-12-18T09:54:15Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89046 | - |
dc.description.abstract | PURPOSE: Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. PATIENTS AND METHODS: Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). RESULTS: Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B-infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C-infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). CONCLUSION: OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B-infected patients. OS was superior in hepatitis C-infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Indoles/therapeutic use* | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Niacinamide/analogs & derivatives* | - |
dc.subject.MESH | Niacinamide/therapeutic use | - |
dc.subject.MESH | Phenylurea Compounds/therapeutic use* | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Pyrroles/therapeutic use* | - |
dc.subject.MESH | Young Adult | - |
dc.title | Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ann-Lii Cheng | - |
dc.contributor.googleauthor | Yoon-Koo Kang | - |
dc.contributor.googleauthor | Deng-Yn Lin | - |
dc.contributor.googleauthor | Joong-Won Park | - |
dc.contributor.googleauthor | Masatoshi Kudo | - |
dc.contributor.googleauthor | Shukui Qin | - |
dc.contributor.googleauthor | Hyun-Cheol Chung | - |
dc.contributor.googleauthor | Xiangqun Song | - |
dc.contributor.googleauthor | Jianming Xu | - |
dc.contributor.googleauthor | Guido Poggi | - |
dc.contributor.googleauthor | Masao Omata | - |
dc.contributor.googleauthor | Susan Pitman Lowenthal | - |
dc.contributor.googleauthor | Silvana Lanzalone | - |
dc.contributor.googleauthor | Liqiang Yang | - |
dc.contributor.googleauthor | Maria Jose Lechuga | - |
dc.contributor.googleauthor | Eric Raymond | - |
dc.identifier.doi | 10.1200/JCO.2012.45.8372 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 24081937 | - |
dc.identifier.url | http://jco.ascopubs.org/content/31/32/4067.long | - |
dc.subject.keyword | Adolescent | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Aged, 80 and over | - |
dc.subject.keyword | Antineoplastic Agents/therapeutic use* | - |
dc.subject.keyword | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.keyword | Carcinoma, Hepatocellular/mortality | - |
dc.subject.keyword | Disease-Free Survival | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Indoles/therapeutic use* | - |
dc.subject.keyword | Kaplan-Meier Estimate | - |
dc.subject.keyword | Liver Neoplasms/drug therapy* | - |
dc.subject.keyword | Liver Neoplasms/mortality | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Niacinamide/analogs & derivatives* | - |
dc.subject.keyword | Niacinamide/therapeutic use | - |
dc.subject.keyword | Phenylurea Compounds/therapeutic use* | - |
dc.subject.keyword | Proportional Hazards Models | - |
dc.subject.keyword | Pyrroles/therapeutic use* | - |
dc.subject.keyword | Young Adult | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 32 | - |
dc.citation.startPage | 4067 | - |
dc.citation.endPage | 4075 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.31(32) : 4067-4075, 2013 | - |
dc.identifier.rimsid | 33763 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.